Results 191 to 200 of about 134,715 (210)

Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial

Lancet, The, 2020
Johanne Silvain, Benoit Lattuca, Farzin Beygui   +2 more
exaly  

Clopidogrel

Reactions Weekly, 2010
openaire   +2 more sources

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

Lancet, The, 2001
Salim Yusuf, Basil S Lewis
exaly  

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

Lancet, The, 2010
Lars Wallentin, Stefan James, Robert F Storey   +2 more
exaly  

Clopidogrel

Reactions Weekly, 2011
openaire   +2 more sources

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

Lancet, The, 2010
Jean-Francois Tanguay, John W. Eikelboom, Christopher B Granger   +2 more
exaly  

Aspirin/aspirin/clopidogrel/clopidogrel

Reactions Weekly
openaire   +1 more source

Clopidogrel

2018
openaire   +1 more source

Clopidogrel

Reactions Weekly, 2005
openaire   +2 more sources

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis

Lancet, The, 2010
Tabassome Simon, Marc S Sabatine
exaly